Business Wire

PAYRETAILERS

Share
PayRetailers Strengthens Its Operations in Latin America

Payment technology solutions have found fertile ground for expansion in Latin America given the lack of financial inclusion in the region, which in turn has put firms in this industry in a favorable business position. Latin America is home to around 300 million digital shoppers, a figure that is expected to grow by more than 20 percent by 2025.

PayRetailers , the main LATAM Fintech's payments specialist, announced the opening of new offices in Peru, a move that will help the company be closer to its customer base and consolidate its presence in one of the fastest growing markets. Moreover, it will enable the company to serve strategic markets throughout Latin America and innovate alongside dynamic financial service providers to offer differentiated and innovative digital experiences to its customers.

Given the myriad opportunities in the region, the company continues to expand its team and technology to build a robust and inclusive payments infrastructure. With a broad offering of card payment solutions and local alternative methods for global businesses expanding into Latin America, today PayRetailers has teams of more than 20 different nationalities and operations in more than 15 countries in Europe and Latin America.

New strategic acquisitions within the region

The company recently acquired two online payment platforms, Paygol of Chile and Pago Digital of Colombia. The two acquisitions strengthen PayRetailers' broad and deep move to tap into the potential of e-commerce payments in Latin America. The agreement gives Paygol and Pago Digital access to PayRetailers' extensive technical expertise, marketing resources and financial investment to grow at a scale.

Understanding the complexities and challenges specific to the continent's markets is one of the biggest challenges the companies looking to expand their operations in the Latin American market need to face. The acquisitions reinforce PayRetailers' position as the leading Fintech payments specialist for Latin America and efforts to simplify B2B e-commerce across the region.

Paygol CEO, Carlos Varas, said, "Paygol believes passionately in the power of local knowledge to bridge international borders. It's a notion we share with PayRetailers as we move forward together to truly unlock the potential of e-commerce businesses across Latin America."

Pago Digital CEO William Talero said, "Pago Digital was founded on a vision of simple and accessible online payments. We have come a long way in 10 years and now we are excited to climb to the next level with PayRetailers: sharing technologies, experience and expertise to bring our customers ever greater opportunities."

Royal Park Partners acted as exclusive financial and strategic advisor to PayRetailers on the acquisition of Pago Digital.

Challenges Fintech companies face for the sake of financial inclusion in Latin America

The Fintech ecosystem in Latin America is performing better year after year; by 2020, there were close to 1,500 parties, including startups, regulators and traditional companies, such as banks. As new technologies such as cryptocurrencies or the metaverse take hold, these organizations have greater challenges to take on as part of the fourth industrial revolution.

According to a survey published in January 2022 by VISA, the growth of the Fintech ecosystem in Latin America can be confirmed by taking into account the 52% increase in financing to the sector.

Latin America experienced the fastest growing e-commerce retail sales boom in the world during 2020. In Mexico, e-commerce grossed nearly 316 billion pesos (US$15 billion) during the year, representing 81% annual growth and accounting for 9% of total retail sales, according to the Mexican online sales association AMVO . The pandemic showed Mexico what it means to be unprepared for the future, making major changes in the daily lives of Mexicans, living in a reality where going out on the street was no longer an option for many people.

To meet the demand, during 2022, Fintech and non-banking companies have been launching solutions such as e-wallets, credit cards and prepaid cards, especially in underserved markets. Digital payments, including through new forms such as QR codes, instant payments or contactless payments, should proliferate among buyers and sellers.

Also of note are regulatory updates and adoption of the blockchain ecosystem in Chile, Argentina, Brazil, Colombia, Costa Rica, El Salvador, Mexico, and Venezuela. El Salvador becomes the first Latin American country to adopt Bitcoin as an official currency as of September 7, 2021, a movement that has been gaining momentum throughout Latin America. As regulation matures around the world, Latin America is proving to be a thriving ground for blockchain development.

With a focus on expanding its customer base and exponentially elevating product reach over the next decade, PayRetailers aims to strengthen verticals such as digital services and e-commerce. Its strategy has allowed it to offer services and occupy spaces not served by traditional payment providers, a player that has to be watched closely in the coming years.

About PayRetailers

PayRetailers is a leading online payment services provider, dedicated to creating a fast and simple payment process for merchants and shoppers. The company offers a full range of payment solutions to help e-commerce companies accept online payments through a single API integration.

A clear understanding of consumer behavior and spending in their specific sector will be the difference between success and failure for merchants looking to expand internationally across certain e-commerce verticals. By accepting local payment methods, PayRetailers allows anyone to make online purchases, even if they don't have credit or debit cards.

PayRetailers is headquartered in Spain, with regional offices in Mexico, Argentina, Brazil, Chile, Colombia, Uruguay and Peru.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye